Search Weight Loss Topics:

Page 33«..1020..32333435..4050..»

Home » Testosterone » Page 33

Several factors can cause or contribute to erectile dysfunction. One example is the medications a person takes. Medicines that affect sex drive, blood flow, and sexual organ function may increase the incidence of erectile dysfunction.

Erectile dysfunction (ED) is the inability to achieve or maintain an erection. It is a common condition that affects males of all ages and varying levels of health and fitness.

This article lists some medications that may cause or contribute to ED, and outlines some treatment options. Finally, we offer some tips to help prevent ED.

Certain medications may contribute to ED, although they are not usually the sole cause of the condition.

A person who suspects their ED may be due to a particular medication should talk to their doctor. Where possible, a healthcare professional may recommend changing the dosage or switching medicines.

A person should not stop taking their medications unless their doctor tells them to do so.

Some medications that may contribute to ED are below.

Anti-hypertensives are prescription medications to help lower blood pressure. They may contribute to ED, though doctors have not yet established why this is the case.

Examples include:

Immunosuppressants reduce the activity of the immune system. A person may take them to help control an autoimmune condition or prevent organ rejection following an organ transplant procedure.

One potential side effect of immunosuppressants is impaired sexual function.

Examples include:

Androgens are hormones associated with male characteristics. Anti-androgens block some aspect of these hormones. Doctors may prescribe them for several conditions, such as heartburn or prostate cancer.

Examples of anti-androgens include:

Gonadotropin-releasing hormone (GnRH) agonists are a class of medications that doctors sometimes prescribe to treat prostate cancer. They may reduce sexual desire in men.

Examples include:

Corticosteroids are drugs that mimic the effects of certain hormones inside the body. People typically take them to help reduce inflammation.

These drugs can also reduce testosterone levels. This may lead to decreased sexual desire and sexual function in some men.

Examples of corticosteroids include:

Antidepressants are medications that doctors may prescribe to treat or prevent the recurrence of clinical depression.

Some antidepressants may inhibit sexual desire, which may affect sexual performance. Others may also delay ejaculation.

Examples of antidepressants that may cause ED include:

Antipsychotics are drugs primarily prescribed for the treatment of psychosis. They may inhibit sexual desire, which may then affect sexual performance.

Examples include:

Anti-epileptics are medications that doctors prescribe to help prevent epileptic seizures. They may affect a mans ability to orgasm.

Examples include:

Aside from medications, some recreational drugs can also affect sexual arousal and performance. Examples include:

Drugs to treat opioid addiction may also lead to erectile dysfunction. These drugs include methadone and buprenorphine.

ED is the medical term for when a person has difficulty achieving or maintaining an erection. While this may occur periodically for all males, those with ED experience more frequent and routine episodes.

The ability to achieve and maintain an erection is dependant on several factors, including:

An issue with any of the above factors may lead to ED.

A doctor may recommend treatments that can enhance sexual performance while allowing a person to continue taking potentially life-saving or life-extending medications. Some examples are below.

Often, ED treatments begin with making changes to a persons routine. These include:

Males who experience mental health issues, such as stress, anxiety, or depression, may also benefit from seeing a mental health professional. These conditions can negatively impact sexual desire and sexual function. As a result, successful treatment may help manage ED.

A doctor may prescribe one of the following medications to help treat ED.

Phosphodiesterase type-5 (PDE 5) inhibitors are medications that relax and widen the blood vessels to promote blood flow. The American Urological Association (AUA) recommend that males take PDE 5 inhibitors 12 hours before having sex.

Examples of PDE 5 inhibitors include:

PDE 5 inhibitors are not suitable for people taking nitrates.

A vasodilator is a medication that helps widen the blood vessels, increasing blood flow.

One potential ED treatment involves injecting the vasodilator directly into the penis or urethra.

According to the AUA, the vast majority of ED cases are due to reduced blood flow to the penis. They add that low testosterone levels may affect a persons sex drive, but are rarely the cause of ED.

If low testosterone levels contribute to ED, a doctor may consider testosterone therapy (TT). This technique involves regularly administering testosterone in one of the following forms:

However, the AUA state that TT does not improve erections in males with normal testosterone levels or in those with low testosterone levels who experience ED as their only symptom.

A vacuum erection device (VED) consists of a plastic tube and a pump. The plastic tube fits over the penis, forming a seal against the bodys skin. Using the pump creates a vacuum around the penis, which causes an erection.

Once the penis is erect, the person slips an elastic ring onto the base of the penis. This retains the blood inside the penis for up to 30 minutes.

According to the AUA, around 75% of males who receive proper training on using a VED can achieve an erection when using these devices.

If lifestyle measures and medical treatments are ineffective, doctors may recommend surgical options for ED. These are outlined below.

The main surgical option for ED is inserting a penile implant. This device sits permanently inside the penis, making it rigid enough for a person to have sex.

There are two types of penile implant:

Vascular surgery for ED helps improve blood flow to the penis. Doctors usually reserve this procedure for younger males with good vascular with ED due to pelvic trauma.

Adopting a healthful lifestyle may help improve a persons physical and mental health, which may reduce the incidence of ED.

Some general tips include:

Erectile dysfunction is a common condition among males of all ages. Certain medications that affect sex drive, blood flow, or sexual organ function may contribute to ED.

Anyone who has concerns that their ED may be due to a particular medication should talk to their doctor. However, people should not stop taking their medicines unless their doctor tells them it is safe.

If it is not possible to switch medications or alter the dose of the existing medication, a doctor may recommend alternative treatments for ED. Possible options include using vacuum erection devices, a penile implant, or sugery.

A person can talk to a healthcare professional to explore suitable treatment options according to their needs.

See the article here:
Medications that cause erectile dysfunction: Types and treatment - Medical News Today

The global Testosterone Replacement Therapy market is broadly analyzed in this report that sheds light on critical aspects such as the vendor landscape, competitive strategies, market dynamics, and regional analysis. The report helps readers to clearly understand the current and future status of the global Testosterone Replacement Therapy market. The research study comes out as a compilation of useful guidelines for players to secure a position of strength in the global Testosterone Replacement Therapy market. The authors of the report profile leading companies of the global Testosterone Replacement Therapy market, such as AbbVie, Endo International, Eli lilly, Pfizer, Actavis (Allergan), Bayer, Novartis, Teva, Mylan, Upsher-Smith, Ferring Pharmaceuticals, Kyowa Kirin, Acerus Pharmaceuticals They provide details about important activities of leading players in the competitive landscape.

The report predicts the size of the global Testosterone Replacement Therapy market in terms of value and volume for the forecast period 2019-2026. As per the analysis provided in the report, the global Testosterone Replacement Therapy market is expected to rise at a CAGR of XX % between 2019 and 2026 to reach a valuation of US$ XX million/billion by the end of 2026. In 2018, the global Testosterone Replacement Therapy market attained a valuation of US$_ million/billion. The market researchers deeply analyze the global Testosterone Replacement Therapy industry landscape and the future prospects it is anticipated to create.

This publication includes key segmentations of the global Testosterone Replacement Therapy market on the basis of product, application, and geography (country/region). Each segment included in the report is studied in relation to different factors such as consumption, market share, value, growth rate, and production.

Get Sample Copy of This Report:https://www.qyresearch.com/sample-form/form/1510148/global-testosterone-replacement-therapy-industry

The comparative results provided in the report allow readers to understand the difference between players and how they are competing against each other. The research study gives a detailed view of current and future trends and opportunities of the global Testosterone Replacement Therapy market. Market dynamics such as drivers and restraints are explained in the most detailed and easiest manner possible with the use of tables and graphs. Interested parties are expected to find important recommendations to improve their business in the global Testosterone Replacement Therapy market.

Readers can understand the overall profitability margin and sales volume of various products studied in the report. The report also provides the forecasted as well as historical annual growth rate and market share of the products offered in the global Testosterone Replacement Therapy market. The study on end-use application of products helps to understand the market growth of the products in terms of sales.

Global Testosterone Replacement Therapy Market by Product: , Gels, Injections, Patches, Other Market

Global Testosterone Replacement Therapy Market by Application: Hospitals, Clinics, Others

The report also focuses on the geographical analysis of the global Testosterone Replacement Therapy market, where important regions and countries are studied in great detail.

Global Testosterone Replacement Therapy Market by Geography:

Methodology

Our analysts have created the report with the use of advanced primary and secondary research methodologies.

As part of primary research, they have conducted interviews with important industry leaders and focused on market understanding and competitive analysis by reviewing relevant documents, press releases, annual reports, and key products.

For secondary research, they have taken into account the statistical data from agencies, trade associations, and government websites, internet sources, technical writings, and recent trade information.

Enquire For Customization in the Report:https://www.qyresearch.com/customize-request/form/1510148/global-testosterone-replacement-therapy-industry

Key questions answered in the report:

Table Of Contents:

Table of Contents 1 Report Overview1.1 Research Scope1.2 Top Testosterone Replacement Therapy Manufacturers Covered: Ranking by Revenue1.3 Market Segment by Type1.3.1 Global Testosterone Replacement Therapy Market Size by Type: 2015 VS 2020 VS 2026 (US$ Million)1.3.2 Gels1.3.3 Injections1.3.4 Patches1.3.5 Other1.4 Market Segment by Application1.4.1 Global Testosterone Replacement Therapy Consumption by Application: 2015 VS 2020 VS 20261.4.2 Hospitals1.4.3 Clinics1.4.4 Others1.5 Study Objectives1.6 Years Considered 2 Global Market Perspective2.1 Global Testosterone Replacement Therapy Revenue (2015-2026)2.1.1 Global Testosterone Replacement Therapy Revenue (2015-2026)2.1.2 Global Testosterone Replacement Therapy Sales (2015-2026)2.2 Testosterone Replacement Therapy Market Size across Key Geographies Worldwide: 2015 VS 2020 VS 20262.2.1 Global Testosterone Replacement Therapy Sales by Regions (2015-2020)2.2.2 Global Testosterone Replacement Therapy Revenue by Regions (2015-2020)2.3 Global Top Testosterone Replacement Therapy Regions (Countries) Ranking by Market Size2.4 Testosterone Replacement Therapy Industry Trends2.4.1 Testosterone Replacement Therapy Market Top Trends2.4.2 Market Drivers2.4.3 Testosterone Replacement Therapy Market Challenges 2.4.4 Porters Five Forces Analysis2.4.5 Primary Interviews with Key Testosterone Replacement Therapy Players: Views for Future 3 Competitive Landscape by Manufacturers3.1 Global Top Testosterone Replacement Therapy Manufacturers by Sales (2015-2020)3.1.1 Global Testosterone Replacement Therapy Sales by Manufacturers (2015-2020)3.1.2 Global Testosterone Replacement Therapy Sales Market Share by Manufacturers (2015-2020)3.1.3 Global 5 and 10 Largest Manufacturers by Testosterone Replacement Therapy Sales in 20193.2 Global Top Manufacturers Testosterone Replacement Therapy by Revenue3.2.1 Global Testosterone Replacement Therapy Revenue by Manufacturers (2015-2020)3.2.2 Global Testosterone Replacement Therapy Revenue Share by Manufacturers (2015-2020)3.2.3 Global Testosterone Replacement Therapy Market Concentration Ratio (CR5 and HHI)3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Testosterone Replacement Therapy as of 2019)3.4 Global Testosterone Replacement Therapy Average Selling Price (ASP) by Manufacturers3.5 Key Manufacturers Testosterone Replacement Therapy Plants/Factories Distribution and Area Served3.6 Date of Key Manufacturers Enter into Testosterone Replacement Therapy Market3.7 Key Manufacturers Testosterone Replacement Therapy Product Offered 3.8 Mergers & Acquisitions, Expansion Plans 4 Market Size by Type4.1 Global Testosterone Replacement Therapy Historic Market Review by Type (2015-2020)4.1.2 Global Testosterone Replacement Therapy Sales Market Share by Type (2015-2020)4.1.3 Global Testosterone Replacement Therapy Revenue Market Share by Type (2015-2020)4.1.4 Testosterone Replacement Therapy Price by Type (2015-2020)4.1 Global Testosterone Replacement Therapy Market Estimates and Forecasts by Type (2021-2026)4.2.2 Global Testosterone Replacement Therapy Sales Forecast by Type (2021-2026)4.2.3 Global Testosterone Replacement Therapy Revenue Forecast by Type (2021-2026)4.2.4 Testosterone Replacement Therapy Price Forecast by Type (2021-2026) 5 Global Testosterone Replacement Therapy Market Size by Application5.1 Global Testosterone Replacement Therapy Historic Market Review by Application (2015-2020)5.1.2 Global Testosterone Replacement Therapy Sales Market Share by Application (2015-2020)5.1.3 Global Testosterone Replacement Therapy Revenue Market Share by Application (2015-2020)5.1.4 Testosterone Replacement Therapy Price by Application (2015-2020)5.2 Global Testosterone Replacement Therapy Market Estimates and Forecasts by Application (2021-2026)5.2.2 Global Testosterone Replacement Therapy Sales Forecast by Application (2021-2026)5.2.3 Global Testosterone Replacement Therapy Revenue Forecast by Application (2021-2026)5.2.4 Testosterone Replacement Therapy Price Forecast by Application (2021-2026) 6 North America6.1 North America Testosterone Replacement Therapy Breakdown Data by Company6.2 North America Testosterone Replacement Therapy Breakdown Data by Type6.3 North America Testosterone Replacement Therapy Breakdown Data by Application6.4 North America Testosterone Replacement Therapy Breakdown Data by Countries6.4.1 North America Testosterone Replacement Therapy Sales by Countries6.4.2 North America Testosterone Replacement Therapy Revenue by Countries6.4.3 U.S.6.4.4 Canada 7 Europe7.1 Europe Testosterone Replacement Therapy Breakdown Data by Company7.2 Europe Testosterone Replacement Therapy Breakdown Data by Type7.3 Europe Testosterone Replacement Therapy Breakdown Data by Application7.4 Europe Testosterone Replacement Therapy Breakdown Data by Countries7.4.1 Europe Testosterone Replacement Therapy Sales by Countries7.4.2 Europe Testosterone Replacement Therapy Revenue by Countries7.4.3 Germany7.4.4 France7.4.5 U.K.7.4.6 Italy7.4.7 Russia 8 Asia Pacific8.1 Asia Pacific Testosterone Replacement Therapy Breakdown Data by Company8.2 Asia Pacific Testosterone Replacement Therapy Breakdown Data by Type8.3 Asia Pacific Testosterone Replacement Therapy Breakdown Data by Application8.4 Asia Pacific Testosterone Replacement Therapy Breakdown Data by Regions8.4.1 Asia Pacific Testosterone Replacement Therapy Sales by Regions8.4.2 Asia Pacific Testosterone Replacement Therapy Revenue by Regions8.4.3 China8.4.4 Japan8.4.5 South Korea8.4.6 India8.4.7 Australia8.4.8 Taiwan8.4.9 Indonesia8.4.10 Thailand8.4.11 Malaysia8.4.12 Philippines8.4.13 Vietnam 9 Latin America9.1 Latin America Testosterone Replacement Therapy Breakdown Data by Company9.2 Latin America Testosterone Replacement Therapy Breakdown Data by Type9.3 Latin America Testosterone Replacement Therapy Breakdown Data by Application9.4 Latin America Testosterone Replacement Therapy Breakdown Data by Countries9.4.1 Latin America Testosterone Replacement Therapy Sales by Countries9.4.2 Latin America Testosterone Replacement Therapy Revenue by Countries9.4.3 Mexico9.4.4 Brazil9.4.5 Argentina 10 Middle East and Africa10.1 Middle East and Africa Testosterone Replacement Therapy Breakdown Data by Type10.2 Middle East and Africa Testosterone Replacement Therapy Breakdown Data by Application10.3 Middle East and Africa Testosterone Replacement Therapy Breakdown Data by Countries10.3.1 Middle East and Africa Testosterone Replacement Therapy Sales by Countries10.3.2 Middle East and Africa Testosterone Replacement Therapy Revenue by Countries10.3.3 Turkey10.3.4 Saudi Arabia10.3.5 U.A.E 11 Company Profiles11.1 AbbVie11.1.1 AbbVie Corporation Information11.1.2 AbbVie Business Overview and Total Revenue (2019 VS 2018)11.1.3 AbbVie Testosterone Replacement Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.1.4 AbbVie Testosterone Replacement Therapy Products and Services11.1.5 AbbVie SWOT Analysis11.1.6 AbbVie Recent Developments11.2 Endo International11.2.1 Endo International Corporation Information11.2.2 Endo International Business Overview and Total Revenue (2019 VS 2018)11.2.3 Endo International Testosterone Replacement Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.2.4 Endo International Testosterone Replacement Therapy Products and Services11.2.5 Endo International SWOT Analysis11.2.6 Endo International Recent Developments11.3 Eli lilly11.3.1 Eli lilly Corporation Information11.3.2 Eli lilly Business Overview and Total Revenue (2019 VS 2018)11.3.3 Eli lilly Testosterone Replacement Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.3.4 Eli lilly Testosterone Replacement Therapy Products and Services11.3.5 Eli lilly SWOT Analysis11.3.6 Eli lilly Recent Developments11.4 Pfizer11.4.1 Pfizer Corporation Information11.4.2 Pfizer Business Overview and Total Revenue (2019 VS 2018)11.4.3 Pfizer Testosterone Replacement Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.4.4 Pfizer Testosterone Replacement Therapy Products and Services11.4.5 Pfizer SWOT Analysis11.4.6 Pfizer Recent Developments11.5 Actavis (Allergan)11.5.1 Actavis (Allergan) Corporation Information11.5.2 Actavis (Allergan) Business Overview and Total Revenue (2019 VS 2018)11.5.3 Actavis (Allergan) Testosterone Replacement Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.5.4 Actavis (Allergan) Testosterone Replacement Therapy Products and Services11.5.5 Actavis (Allergan) SWOT Analysis11.5.6 Actavis (Allergan) Recent Developments11.6 Bayer11.6.1 Bayer Corporation Information11.6.2 Bayer Business Overview and Total Revenue (2019 VS 2018)11.6.3 Bayer Testosterone Replacement Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.6.4 Bayer Testosterone Replacement Therapy Products and Services11.6.5 Bayer SWOT Analysis11.6.6 Bayer Recent Developments11.7 Novartis11.7.1 Novartis Corporation Information11.7.2 Novartis Business Overview and Total Revenue (2019 VS 2018)11.7.3 Novartis Testosterone Replacement Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.7.4 Novartis Testosterone Replacement Therapy Products and Services11.7.5 Novartis SWOT Analysis11.7.6 Novartis Recent Developments11.8 Teva11.8.1 Teva Corporation Information11.8.2 Teva Business Overview and Total Revenue (2019 VS 2018)11.8.3 Teva Testosterone Replacement Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.8.4 Teva Testosterone Replacement Therapy Products and Services11.8.5 Teva SWOT Analysis11.8.6 Teva Recent Developments11.9 Mylan11.9.1 Mylan Corporation Information11.9.2 Mylan Business Overview and Total Revenue (2019 VS 2018)11.9.3 Mylan Testosterone Replacement Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.9.4 Mylan Testosterone Replacement Therapy Products and Services11.9.5 Mylan SWOT Analysis11.9.6 Mylan Recent Developments11.10 Upsher-Smith11.10.1 Upsher-Smith Corporation Information11.10.2 Upsher-Smith Business Overview and Total Revenue (2019 VS 2018)11.10.3 Upsher-Smith Testosterone Replacement Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.10.4 Upsher-Smith Testosterone Replacement Therapy Products and Services11.10.5 Upsher-Smith SWOT Analysis11.10.6 Upsher-Smith Recent Developments11.11 Ferring Pharmaceuticals11.11.1 Ferring Pharmaceuticals Corporation Information11.11.2 Ferring Pharmaceuticals Business Overview and Total Revenue (2019 VS 2018)11.11.3 Ferring Pharmaceuticals Testosterone Replacement Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.11.4 Ferring Pharmaceuticals Testosterone Replacement Therapy Products and Services11.11.5 Ferring Pharmaceuticals SWOT Analysis11.11.6 Ferring Pharmaceuticals Recent Developments11.12 Kyowa Kirin11.12.1 Kyowa Kirin Corporation Information11.12.2 Kyowa Kirin Business Overview and Total Revenue (2019 VS 2018)11.12.3 Kyowa Kirin Testosterone Replacement Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.12.4 Kyowa Kirin Testosterone Replacement Therapy Products and Services11.12.5 Kyowa Kirin SWOT Analysis11.12.6 Kyowa Kirin Recent Developments11.13 Acerus Pharmaceuticals11.13.1 Acerus Pharmaceuticals Corporation Information11.13.2 Acerus Pharmaceuticals Business Overview and Total Revenue (2019 VS 2018)11.13.3 Acerus Pharmaceuticals Testosterone Replacement Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.13.4 Acerus Pharmaceuticals Testosterone Replacement Therapy Products and Services11.13.5 Acerus Pharmaceuticals SWOT Analysis11.13.6 Acerus Pharmaceuticals Recent Developments 12 Supply Chain and Sales Channels Analysis 12.1 Supply Chain Analysis 12.2 Sales Channels Analysis12.2.1 Testosterone Replacement Therapy Sales Channels12.2.2 Testosterone Replacement Therapy Distributors12.3 Testosterone Replacement Therapy Customers 13 Estimates and Projections by Regions (2021-2026)13.1 Global Testosterone Replacement Therapy Sales Forecast (2021-2026)13.1.1 Global Testosterone Replacement Therapy Sales Forecast by Regions (2021-2026)13.1.2 Global Testosterone Replacement Therapy Revenue Forecast by Regions (2021-2026) 13.2 North America Market Size Forecast (2021-2026)13.2.1 North America Testosterone Replacement Therapy Sales Forecast (2021-2026)13.2.2 North America Testosterone Replacement Therapy Revenue Forecast (2021-2026)13.2.3 North America Testosterone Replacement Therapy Size Forecast by County (2021-2026) 13.3 Europe Market Size Forecast (2021-2026)13.3.1 Europe Testosterone Replacement Therapy Sales Forecast (2021-2026)13.3.2 Europe Testosterone Replacement Therapy Revenue Forecast (2021-2026)13.3.3 Europe Testosterone Replacement Therapy Size Forecast by County (2021-2026) 13.4 Asia Pacific Market Size Forecast (2021-2026)13.4.1 Asia Pacific Testosterone Replacement Therapy Sales Forecast (2021-2026)13.4.2 Asia Pacific Testosterone Replacement Therapy Revenue Forecast (2021-2026)13.4.3 Asia Pacific Testosterone Replacement Therapy Size Forecast by Region (2021-2026) 13.5 Latin America Market Size Forecast (2021-2026)13.5.1 Latin America Testosterone Replacement Therapy Sales Forecast (2021-2026)13.5.2 Latin America Testosterone Replacement Therapy Revenue Forecast (2021-2026)13.5.3 Latin America Testosterone Replacement Therapy Size Forecast by County (2021-2026) 13.6 Middle East and Africa Market Forecast13.6.1 Middle East and Africa Testosterone Replacement Therapy Sales Forecast (2021-2026)13.6.2 Middle East and Africa Testosterone Replacement Therapy Revenue Forecast (2021-2026)13.6.3 Middle East and Africa Testosterone Replacement Therapy Size Forecast by County (2021-2026) 14 Research Findings and Conclusion 15 Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source15.2 Author Details15.3 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

See the original post here:
Testosterone Replacement Therapy Market Overview, Development History And Forecast To Shared In Latest Research Report 2020-2026 |Endo International,...

When it comes to bodybuilders, athletes, or fitness junkies looking to get the edge with their gains, taking growth hormone (GH) is a highly sought after option. Growth hormone is a peptide hormone used to stimulate growth, cell reproduction and regeneration, and is vital for human development. Getting that shredded physique is something we all seek and when done right, big gains comes from growth hormone use. It is when its abused that things start to go awry.

We sat down with Dr. Testosterone to discuss growth hormone and the short term and long term effects of using it. How it works, why its prescribed, and the role it plays with acne are all key questions Dr. Testosterone addressed for us. We even took on the challenge of asking him whether conventional steroids or selective androgen receptor modulators (SARMs) were more effective for bodybuilding.

Dr. Testosterone is one a small selection of certified doctors whose mission is to improve the health and safety of bodybuilders. As someone who understands the laws and regulation surrounding steroid and PED use, he does his best to educate bodybuilders on the safest ways to enhance their overall physique and performance while staying the most safe. In our latest GI Exclusive interview, Dr. Testosterone talks about the truth surrounding growth hormone and the effects abuse can have on the body.

Growth hormone is a peptide hormone used to stimulate growth, cell reproduction and regeneration, and is used as anabolic agent for performance enhancements. It is prescribed for those with Dwarfism, Turner Syndrome, HIV/AIDS patients who suffered from muscle wasting, and recovery and recuperation post-surgery (1).

How growth hormone works is that all organs have receptors or Insulin-like growth factor 1 (IGF-1) and when released, it works as a fat burner and can aid in cell recovery and recuperation. When we fast, we burn through growth hormone. Once it exceeds a certain limit, then we start to see skeletal muscle growth and visceral muscle growth, but also the negative effects.

In the short term, negative side effects of abused growth hormone include carpal tunnel syndrome and a pre-diabetic state. Growth hormone is responsible for the swelling which causes compression of your wrist tendons that pinch your medial nerve. Surgery is required to release this tension (2). Since GH liberates glucose from your liver into the blood stream, glycemia can occur. With little cardio and an elevated glycemic state, this can lead to Type 2 diabetes which is often why people take Insulin along with growth hormone as a regulator.

In the long term, while abuse may come with muscle growth, you are at an added risk of more severe side effects. Enlarged organs become a serious risk as a result of organomegaly and cardiomegaly. Enlarged jaw, cheekbones, forehead and other internal organs become enlarged and your heart can seriously increase in size causing its own series of side effects. Thicker skin, enlarged nose, lips, and tongue, and potential tumor growth if predisposed are all other effects that may come from GH abuse.

When taking steroids, many report increased acne which can cause pain but can also just be uncomfortable and hurt your confidence. Since acne effects everyone at different times and is very common, there are many ways to treat acne, some naturally and others may require a doctor. Acne is a result of dihydrotestosterone (DHT) which is an androgen metabolite of testosterone (3). DHT stimulates the production of oil that leads to clogged glands and pores and often times these are unable to release oil leading to inflammation. Steroids metabolize to estrogen in the body and then to DHT causing all of the above.

Anti-androgens are one way to treat this but they may block DHT and you may feel the effects of low sex drive and depression. Other creams or antibiotics, purified alcohol, or UV light can also help. Diet is a key natural way to reduce acne and eating clean goes a long way. Avoiding trans or saturated fat is big, but consuming unsaturated fatty acids like fish oil can be very beneficial. Sugar causes inflammation through Insulin so removing as much sugar from your diet as you can is also a big bonus (4).

While this may be a matter of opinion, Dr. Testosterone is a trusted voice when it comes to something like this topic. To start, selective androgen receptor modulators (SARMs) are a new kind of androgenic drug claiming to have more uses than your conventional steroids (5). The issue with many people is that this is still new and regulated like conventional steroids. Still with a gray area surrounding this treatment, many are suspicious without further evidence to back up claims that they have the same effects as anabolic steroids, but could be faked with other things that arent regulated.

For Dr. Testosterone, he feels comfortable with conventional steroids because theyve been around for a very long time, amassing ample evidence as to their ability to work properly. Instead of going to the new kid on the block, we use pharmaceutical grade, legitimate steroids where we know of the side effects and proper dosages.

Dr. Testosterone enlightened us with new and valuable information about growth hormones and the negative effects that come with too much. While trying to get to the next level is something we should all strive for, knowing how to safely and effectively do so is incredibly important. As someone who understands the science and the law behind these drugs, Dr. Testosterone is a great source of knowledge for all of us looking for that valuable information. Check out this GI Exclusive to learn more about growth hormone, the negative effects, and other aspects of health and safety to know when looking into something like this.

Let us know what you think in the comments below.Also, be sure to follow Generation Iron onFacebook, Twitter, andInstagram.

*Images courtesy of Envato

References

The rest is here:
Growth Hormones Vs Steroids Vs SARMs: Everything You Need To Know | Dr. Testosterone - generationiron.com

A MAN who made a documentary about his first year on testosterone during his transition has won a national filmmakingaward.

Ben Hodge, from Rainhill, faced difficulty and bullying after coming out as trans.

However last year, as he started transitioning, he filmed his journey in a documentary called 1 year: A letter to my 14 year old self.

The film shows the highs and lows of Ben finding himself and thoughts throughout the process.

His film has now been shortlisted for the Best Documentary Category of the Into Film Awards sponsored by The National Lottery.

The Into Film Awards were due to take place on March 18 at Londons ODEON Luxe Leicester Square, however due to coronavirus it took place online and was hosted by David Walliams OBE.

Ben, 20, took the Best Documentary prize for his film.

He said: "I can't believe that my film which started out as an idea for a Facebook post has made it this far. It's truly an honour.

"Something I think that is important to note is that no two LGBT+ experiences are the same.

"But I hope that by sharing my experiences, I can open some level of understanding and tolerance in my audience.

Bens film sees him writing a letter to his younger self about the myriad of ways his life has improved in the last five years, and also charts his first year on testosterone as he transitions to becoming the person he truly is.

Ben is currently studying Media & Performance at the University of Salford and is an amateur filmmaker and theatre creator with a particular interest in stories regarding LGBTQ+ experiences.

Ben before his transition

He also has an interest in stand-up comedy, drawing on his experiences as an openly gay transgender man to make light of things that otherwise might not be discussed.

This has taken him around the country, from Manchester all the way to the Edinburgh Fringe.

1 Year has been screened across the globe, from a UNICEF talk about youth filmmaking and creating empathy in Kathmandu, Nepal to the Geelong Pride Film Festival in Australia and a current LGBT+ History Month exhibition at the University of Salford.

Ben is currently making a film about St Helens and how the closing of the mining industry affected the town and culture.

He wants to screen the final product in a community cinema.

The Into Film Awards celebrate exceptional talent from children and young people aged 5 19 years old who have demonstrated impressive achievements in filmmaking and film reviewing.

Host for the 2020 Awards, David Walliams said: I love the Into Film Awards because it gives the opportunity to young people, from all kinds of backgrounds, to be a part of the film industry.

"As an actor, these young people are the future, and you want them to give you a job one day!

"Anything that encourages creativity is important, we have an amazing film industry in this country which is often ignored by politicians and we need to support it.

"Into Film is an amazing charity."

For more information intofilm.org/Awards

The rest is here:
Student from Rainhill honoured at The Into Film Awards - St Helens Star

Final Report will add the analysis of the impact of COVID-19 on this industry.

November 2020:

The global Testosterone Replacement Therapy Market research report offers all the vital data in the domain. The latest report assists new bees as well as established market participants to analyze and predict the Testosterone Replacement Therapy market at the regional as well as global level. It covers the volume [k MT] as well as revenues [USD Million] of the global Testosterone Replacement Therapy market for the estimated period. Numerous key players AbbVie, Inc., Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Company, Kyowa Kirin International plc, Pfizer, Inc., Acerus Pharmaceuticals Corporation, and Perrigo Company plc. are dominating the global Testosterone Replacement Therapy market. These players hold the majority of share of the global Testosterone Replacement Therapy market.

DownloadSamplecopy + All Related Graphs & Charts @: https://www.coherentmarketinsights.com/insight/request-sample/2024

The data presented in the global Testosterone Replacement Therapy market offers budding opportunities, which help users to make strategic moves and prosper their business. The report highlights the impact of numerous factors that might result in obstructing or propelling the Testosterone Replacement Therapy market at global as well as local level. The global Testosterone Replacement Therapy market research report offers the summary of key players dominating the market including several aspects such as their financial summary, business strategy, and most recent developments in these firms.

Detailed Segmentation:

By Active Ingredient TypeTestosteroneMethyl TestosteroneTestosterone UndecanoateTestosterone EnanthateTestosterone CypionateBy Route of AdministrationInjectablesParenteral

By Region

North America (U.S., Canada, Mexico)

Asia Pacific (India, China, Japan, South Korea, ASEAN, Rest of Asia Pacific)

Europe (Italy, Germany, France, Spain, Central & Eastern Europe, Rest of Europe)

Middle East & Africa (GCC, Turkey, Rest of the Middle East & Africa)

South America (Brazil, Argentina, Rest of South America)

The study encompasses profiles of major companies operating in the Testosterone Replacement Therapy Market. Key players profiled in the report includes: AbbVie, Inc., Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Company, Kyowa Kirin International plc, Pfizer, Inc., Acerus Pharmaceuticals Corporation, and Perrigo Company plc.

Key points of the global Testosterone Replacement Therapy market

The oretical analysis of the global Testosterone Replacement Therapy market stimulators, products, and other vital facets

Recent, historical, and future trends in terms of revenue and market dynamics are reported

Pin-point analysis of the competitive market dynamics and investment structure is predicted to grow

Future market trends, latest innovations, and various business strategies are reported

Market dynamics include growth influencers, opportunities, threats, challenges, and other crucial facets

The global Testosterone Replacement Therapy market research report offers users with an all-inclusive package of market analysis that includes current market size, expansion rate, and value chain analysis. The global Testosterone Replacement Therapy market is segmented on a regional basis Europe, North America, Latin America, Asia Pacific, and Middle East & Africa as well. To offer a comprehensive view and competitive outlook of the global Testosterone Replacement Therapy market, our review team employs numerous methodological procedures, for instance, Porters five forces analysis.

This research report includes the analysis of various Testosterone Replacement Therapy market segments. The bifurcation of the global market is done based on its present and prospective inclinations. The regional bifurcation involves the present market scenario in the region along with the future projection of the global Testosterone Replacement Therapy market. The global market report offers an overview of expected market conditions due to changes in the technological, topographical, and economic elements.

Need a discount?

Note: *The discount is offered on the Standard Price of the report.

Ask for the discount @ https://www.coherentmarketinsights.com/insight/request-discount/2024

Questions answered in the report include

What is the expected market size by the end of the forecast period?

What are the major factors initiating the global Testosterone Replacement Therapy market growth?

What are the latest developments and trending market strategies that are influencing the growth of the Testosterone Replacement Therapy market?

What are the key outcomes of the Testosterone Replacement Therapy market developments?

Who are the key players in the market?

What are the opportunities and challenges faced by the key players?

Key Reasons for Purchasing Global Testosterone Replacement Therapy Market Report

New approaches and latest development trend that describe the structure of the market

Advanced market breakdown structure

Historical data and future market scope

In-depth market analysis based on statistics, growth stimulators, and market developments

Statistical data representation through figurative, numerical, and theoretical elaboration

Report provides insight of the business and sales activities

Why Coherent Market Insights:

Explore extensive library of market reports

Accurate and Actionable insights

Focus on Key Trends and Market Movements

Critical Consulting Project Execution

24/7 Online and Offline Support

Most-detailed market segmentation

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations

Promo-code: CMIFIRST1000

Buy This Complete A Business Report @:https://www.coherentmarketinsights.com/insight/buy-now/2024

NOTE:Our team is studying Covid-19 and its impact on various industry verticals and wherever required we will be considering Covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details

Interested about who is winning the race of COVID-19 Vaccine. Coherent Market Insights (CMI)

providesCOVID-19 Vaccine Trackerfor all the latest updates about COVID-19 Vaccine.

Customization of the Report:

If you do not think that you are looking into Artificial Pancreas Device Systems report or need any clear preconditions, please contact our custom research team at(sales@coherentmarketinsights.com)

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:Mr. ShahCoherent Market Insights1001 4th Ave,#3200Seattle, WA 98154Tel: +1-206-701-6702Email: sales@coherentmarketinsights.com

See the original post here:
Increase in the Adoption of Testosterone Replacement Therapy to Propel the Growth of the Testosterone Replacement Therapy Market Between 2020-2027 -...

Transparency Market Research (TMR)has published a new report titled, Testosterone Replacement Therapy Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20192027.According to the report, the globalTestosterone Replacement Therapy marketwas valued atUS$ 1,613.7 Mnin2018and is projected to expand at a CAGR of4.4%from2019to2027.

Overview

Request Brochure for Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1097

Growing Awareness about Testosterone Replacement Therapy to Drive Market

Request for Analysis of COVID19 Impact on Testosterone Replacement Therapy Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1097

North America to Dominate Global Market

Buy Testosterone Replacement Therapy Market Report

https://www.transparencymarketresearch.com/checkout.php?rep_id=1097&ltype=S

Competitive Landscape

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

See the rest here:
Testosterone Replacement Therapy Market projected to expand at a CAGR of 4.4% from 2019 to 2027 - Eurowire

Testosterone Therapy Marketresearch report is the new statistical data source added byA2Z Market Research.

Testosterone Therapy Market is growing at a High CAGR during the forecast period 2020-2026. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Testosterone Therapy Marketreport focused on the comprehensive analysis of current and future prospects of the Testosterone Therapy industry. This report is a consolidation of primary and secondary research, which provides market size, share, dynamics, and forecast for various segments and sub-segments considering the macro and micro environmental factors. An in-depth analysis of past trends, future trends, demographics, technological advancements, and regulatory requirements for the Testosterone Therapy market has been done in order to calculate the growth rates for each segment and sub-segments.

Get Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

https://www.a2zmarketresearch.com/sample?reportId=115440

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Vendors of this Market are:

AbbVie Inc, Actavis Inc, Eli Lilly & Co, Auxilium Pharmaceuticals.

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Testosterone Therapy market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Testosterone Therapy markets trajectory between forecast periods.

The report provides insights on the following pointers:

Market Penetration:Comprehensive information on the product portfolios of the top players in the Testosterone Therapy market.

Product Development/Innovation:Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Market Development:Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

Market Diversification:Exhaustive information about new products, untapped geographies, recent developments, and investments in the Testosterone Therapy market.

Get up to 30% Discount on this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=115440

Regions Covered in the Global Testosterone Therapy Market Report 2020:The Middle East and Africa(GCC Countries and Egypt)North America(the United States, Mexico, and Canada)South America(Brazil etc.)Europe(Turkey, Germany, Russia UK, Italy, France, etc.)Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

The cost analysis of the Global Testosterone Therapy Market has been performed while keeping in view manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy taken into consideration.

Reasons for buying this report:

Table of Contents

Global Testosterone Therapy Market Research Report 2020 2026

Chapter 1 Testosterone Therapy Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Testosterone Therapy Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=115440

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

See original here:
Comprehensive Report on Testosterone Therapy Market 2020 | Size, Growth, Demand, Opportunities & Forecast To 2026 | AbbVie Inc, Actavis Inc, Eli...

Read the Full Video Transcript

Alicia Morgans: Hi, my name is Alicia Morgans and I'm a GU medical oncologist and Associate Professor of Medicine at Northwestern University. I am so excited to have here with me today, Dr. Dan Spratt, who is a Professor of Radiation Oncology at the University of Michigan, and he will be talking to us about the role of ADT in men who are receiving radiation therapy. Thank you so much, Dr. Spratt.

Daniel Spratt: Thank you so much, Dr. Morgans. It's great to be here talking about this topic, which is, obviously close to me as a radiation oncologist and I have no relevant disclosures for this talk. And so, before I get into the role of hormone therapy with radiation, I think it's important to take a step back real quick about just the role of hormone therapy in prostate cancer.

The very first case of prostate cancer was in the mid 1800s, and it took almost a hundred years before the first effective treatment for prostate cancer really emerged, which Dr. Huggins and Hodges won a Nobel Prize for, with surgical castration showing us improved outcomes for men with metastatic prostate cancer. And then it took another 40 years for the first FDA approved agent, leuprolide, which is an LHRH agonist, which suppresses testosterone, which is still likely the most common form of hormone therapy used today, at least the United States. And then shortly thereafter, one of the first anti-androgens was approved, flutamide, which is a drug given usually three times a day.

But, there was quite a bit less progress the next 20 years. There was docetaxel, but the next big drug in the category was degarelix, which was the first GnRH antagonist approved in 2008. And then the past 12 years or so, new drugs had exploded, many of which were hormone therapy or AR signaling inhibitor drugs, including abiraterone, enzalutamide, apalutamide as well as darolutamide, and numerous other approvals shown here.

And so, while this was all ongoing, the study of radiotherapy with hormone therapy was occurring in parallel. And so, one of the very first studies was an old RTOG trial in the mid 1970s. It was a pretty big trial, 566 patients. This is how they used to stage prostate cancer back then. But these were very advanced node-positive prostate cancer, and it was a question nothing to do with hormone therapy. It was about how much radiation could you give to the lymph nodes. But they found on a very simple multi-variable analysis, that the use of hormones, which really this is hormone therapy or ADT, had a trend for improvement in what they called local control, which was just measured by a rectal exam.

And this was a promising enough signal they ran a Phase II trial shortly thereafter of 30 patients, all accrued in one year. And again, really bulky primary tumors and clinical node-positive disease. And they gave four months of an LHRH agonist and flutamide. At that time, how they assessed response was the DRE, and 28 of the 30 patients, they said had primary tumor clearance, measured by DRE, because these were stuck in bulky primaries.

Then subsequently, they followed this with a Phase III trial. And again, this was very locally advanced disease. You could have lymph nodes all the way up into the para-aortic nodes, which today we would call metastatic disease, and they randomized radiation therapy upfront, versus radiation therapy plus hormone therapy with just an LHRH agonist until progression. Those in arm one, they would add hormone therapy at time of relapse. And this is really one of the first randomized trials that showed that there was a reduction in metastatic disease in men receiving hormone therapy, as well as a improvement in survival, at least for the high Gleason score tumors, Gleason 8 to 10.

This in parallel, was done with, again, a trial where in non-metastatic patients, at least by the imaging at the time, with very bulky primaries, so this is a 25 cm2 gland. These are very big prostates. It was radiation alone +/- 4 months of combined androgen blockade, and as you see here, improvements in prostate cancer-specific mortality and a trend, but didn't lead significance for improvement in overall survival. So this was really the dawn of the era.

I won't go through, there's probably about 40 other trials, and this slide sort of is a highlight reel that over the next 30 years, there's been many trials assessing the addition of hormone therapy, assessing various durations of hormone therapy, some assessing use of neoadjuvant hormone therapy before radiation, some assessing adjuvant and prolonged adjuvant. And the summary of all of this work to oversimplify it is that in today's risk grouping, we usually use NCCN risk groups, for low-risk men, often now we don't even treat them with upfront therapy like radiation, but we definitely don't add hormone therapy. For select intermediate-risk men, we often, from these studies learn, we should be adding 4 to 6 months of a short-term hormone therapy. And for our higher risk men, to give them longer term, usually 18 to 28 months of hormone therapy.

This is hot off the press. We just presented this work last week and this paper will be published in JCO soon, and so people watching this can see the conclusions. We did a meta analysis of the two trials of intermediate-risk patients, where I just said you can give short-term hormone therapy, and we were trying to figure out that optimal timing of it, whether you should use an adjuvant or a neoadjuvant approach. And in this meta analysis of randomized trials, what we found, interestingly, was that all endpoints favored, that were significant, except for PCSM and overall survival, all favored the use of this adjuvant approach with the winning arm here. So, sequencing, in addition to duration, may be very important.

And so, all of what I've talked about so far is really oncologic outcomes, survival-type outcomes, but that's really only half the story when you're talking about hormone therapy, because quality of life is equally important, and to some patients, potentially more important to them. And it's very easy for scientists and researchers and clinicians to focus on the tumor response, but we really need to be weighing the harm, or the efficacy of our drugs to cancer, versus to the patient itself. We all too often focus when we look at things, like hormone therapy, on does it include the PSA values or various imaging results or the rectal exam findings and that early study of tumor progression. But we must remember that our treatments can harm quantity and quality of life in select patients.

And so, one of these studies, I like to always highlight is a big randomized trial done, called RTOG 96-01, which is a trial of men with recurrent prostate cancer that were randomized to receive radiation with either a placebo, or 2 years of high-dose bicalutamide and antiandrogen by itself. And what we've shown is that in men receiving early salvage radiation therapy, there's a two-fold increased risk of other cause mortality, dying of something other than prostate cancer, which was driven by a high-grade, predominantly cardiac toxicity, about a three-fold increase. This has been shown in select other studies with high-dose bicalutamide, and so again, we can't just focus on improvements in biochemical recurrence, we need to think about the overall benefit to the patient.

So hormone therapy has a variety of side effects discussed. On the right, in pink here, these are often metabolic-type side effects. On the left, these are very common things we think about. Loss of libido, erectile dysfunction, hot flushes. So some are mild, some are annoyances, but some can be serious for select patients. One that's often not probably discussed enough as this is a large meta analysis of over 150,000 patients, is hormone therapy has been shown, likely, to increase the risk of development of depression, and depression can be of various scales and severity, and so is important. And NCCN guidelines has a screening tool for this for patients.

One of the other issues with hormone therapy, especially when we're talking about with radiation where we're usually giving it for a finite period of time, it's not usually a lifelong, it's for 6 months or 18 months, is this is one of those trials that established, that compare 18 months of hormone therapy versus 36 months of hormone therapy with radiation. And although that's the duration they intended to give, it takes a long time to recover testosterone. And what you see here, is that it takes almost over double the duration that was given to recover. So for 18 months of hormone therapy, it took 3.5 years to recover back to normal testosterone, and for the 36 months, took a total of 6.6 years. And that's from initiation of hormone therapy. But what's also is important as you see that, despite this very long-term follow-up, 20% to 40% of men never even recovered back to normal testosterone levels.

This is similar and this surprises a lot of people when they actually look at this data that you've been short-term hormone therapy for 6 months is that you can see here, this is just the timing of hormone therapy, but it's 6 months in both arms, that again, starting at the initiation of that hormone therapy, keeps it low for 6 months, but it took almost an additional year for most men to get back up to normal testosterone, and still, about 20% of men have still not recovered to normal testosterone by years after treatment.

And so, it is exciting, and this is other work we presented recently, as well as this is published in the New England Journal, is the use of this novel GnRH antagonist called relugolix. Prior to the randomized trial I'll show you, they ran a Phase II randomized trial of this novel oral GnRH antagonist, relugolix, compared it to degarelix, the drug that I told you that was approved in 2008 that's an injectable given monthly, and both showed very good sustained castration levels over this 24-week period, but actually, relugolix had faster time, slightly, to achieve castration, but also a faster recovery time of testosterone after.

And what's even more impressive is their Phase III trial, which the majority of patients probably in the United States don't use degarelix, they receive leuprolide or something like leuprolide, and this was a big multi-national trial, over 900 patients. It's a registration trial, trying to get approval for relugolix. It was designed as a non-inferiority trial to achieve sustained castration of testosterone levels over a 48-week period with multiple secondary endpoints. A subset of these patients, given those talks about the use of radiation, that subset of these patients, about 150 of them, received radiation therapy with one of the two forms of hormone therapy, and it was primarily external beam radiation with the primary or curative setting or the salvage setting where we often deliver radiation therapy.

What you see here on the left, this are the overall trial results. Relugolix was not only non-inferior, it was actually superior to leuprolide, where 96.7% of patients had sustained castrate rate levels of testosterone, versus 88.8% with leuprolide. And similarly, as would be expected, those in the radiation therapy cohort had similar excellent sustained castration with the use of relugolix.

The secondary endpoints are also very interesting. They looked at, in the first column here, is testosterone suppression less than 50 nanograms per deciliter, but by day 4. And so what's amazing is, almost 60% of patients that received relugolix, and this is again, the radiation therapy subset, already had castrate testosterone and obviously none with leuprolide. And even by day 15, all the patients with relugolix were already castrate, and only 10% with leuprolide. And as even you can see with PSA responses that, of course, the testosterone goes down as expected, the PSA responds as well.

That's one of the advantages is this early, the left side of this, is comparing testosterone levels over time, as it's more rapidly you achieve castration, but it's very interesting as the tail of these curves. As I showed you with leuprolide, it can take years to recover to normal testosterone. Relugolix, you can see that within 90 days, which is just 3 months, over half of the men already had achieved normal testosterone levels. So this is something unprecedented that will allow future studies to tailor the on-and-off switch of how long you actually really want them to be under hormone therapy or castration.

And finally, a very exciting area that has been shown signals in other trials and studies, is they also showed this was not a pre-specified endpoint, but they did pre-specify they'd collect this data for safety, is they showed a significant reduction in major adverse cardiac events, which, as I showed you from that prior study of use of bicalutamide, for example, a substantial increase in risk of cardiac events. And so again, this is something, combined with prior data, that's at least promising, interesting, that requires further study.

So I think in summary, hormone therapy or ADT improves many important oncologic outcomes for men treated with radiation therapy. It's been shown in the correct patient populations to reduce recurrence of disease, reduce the development of metastasis, and even helps many men live longer. But we also must balance this with the side effects of hormone therapy, and we must personalize this risk-benefit ratio. Many of the side effects are minor annoyances, especially with short-term therapy, but some may be serious and patients need to be counseled on this. What is very exciting, as newer forms of ADT, especially a novel oral GnRH antagonist, if approved, does have, especially in combination of radiation therapy, many advantages given it's fast on-and-off mechanism, potentially, this cardiac reduction in side effects as well. So thank you so much.

Read more from the original source:
The Role of ADT in Men Being Treated with Radiation Therapy Presentation - Michael Cookson, Alicia Morgans & Daniel Spratt - UroToday

Transparency Market Research (TMR) has published a new report titled, Testosterone Replacement Therapy Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20192027. According to the report, the globalTestosterone Replacement Therapy marketwas valued at US$ 1,613.7 Mn in 2018 and is projected to expand at a CAGR of 4.4% from 2019 to 2027.

Overview

Growing Awareness about Testosterone Replacement Therapy to Drive Market

Request For Covid19 Impact Analysis https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1097

North America to Dominate Global Market

Buy Report Now :https://www.transparencymarketresearch.com/checkout.php?rep_id=1097&ltype=S

Read our Case study at :https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up

Competitive Landscape

The global Testosterone Replacement Therapy market has been segmented as follows:

More Trending Reports by Transparency Market Research 1.https://www.prnewswire.com/news-releases/global-chronic-obstructive-pulmonary-disease-copd-treatment-market-to-reach-us-26-2-bn-in-2027-drug-makers-focus-on-combination-therapies-transparency-market-research-301011476.html

See the rest here:
Testosterone Replacement Therapy Market Increasing Demand with Leading Player, Comprehensive Analysis, Forecast 2027 - The Think Curiouser

Pop songs about marijuana have been around for decades. Theres Steppenwolfs Dont Step on the Grass, Sam from 1968 and Miley Cyrus Dooo It from 2015. But now that medical and recreational marijuana and CBD (cannabidiol, the active compound in pot) are legal in many states, folks have decided it must be good for health, not just entertainment.

A new study in JAMA looked at a forum on Reddit that has more than 100,000 folks sharing their experiences using CBD. Some claim CBD can treat autism and mental health problems, others tout the chemical for orthopedic discomfort, insomnia and neurological, gastrointestinal, dermatological, oral and ophthalmologic conditions.

Theres scant data on the effectiveness of CBD in treating many of these conditions, so you dont want to ignore proven medical approaches that can improve, and even save, your life.

Unproven use of CBD can cause liver injury, drug interactions and mood changes. Animal studies show CBD can interfere with the development and function of testes and sperm, decrease testosterone levels and impair sexual behavior in males. A new lab study found when pregnant females are regularly exposed to cannabis, their offspring have long-term cognitive deficiencies, asocial behavior and anxiety in adulthood.

However, studies do indicate some CBD benefits for pain, insomnia and two rare forms of childhood epilepsy (the only FDA-approved use).

The bottom line: Dont let CBD fog up your decision-making so that you opt for unhealthy choices for treating serious health issues. Ask your doc if and when it may be appropriate for you.

Mehmet Oz, M.D., is host of The Dr. Oz Show, and Mike Roizen, M.D., is chief wellness officer emeritus at Cleveland Clinic. To live your healthiest, tune into The Dr. Oz Show or visit http://www.sharecare.com.

See the article here:
Putting the brakes on CBD self-treatments - The Union Leader

Page 33«..1020..32333435..4050..»

Home » Testosterone » Page 33